MannKind reports Q4 EPS 3c, consensus 3c

Reports Q4 revenue $76.8M, consensus $74.98M. Reports reduced debt principal by $236M; remaining convertible debt of $36M; Year-end 2024 cash, cash equivalents and investments of $203M…Advanced pipeline: Reported primary endpoint of INHALE-1 for Afrezza in pediatrics; Progressed MNKD-101 to Global Phase 3 and completed Phase 1 of MNKD-201…”Throughout 2024, we accomplished the milestones we outlined at the beginning of the year, including delivering robust revenues as we exited the year with an annual run rate of $300 million,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind (MNKD) Corporation. “We are thrilled to have welcomed Dominic Marasco as President, Endocrine Business Unit, positioning Afrezza for further growth, including a planned submission this summer to seek approval in the pediatric population. In our orphan lung clinical programs, nintedanib DPI is progressing to the next phase of development and our Phase 3 trial of clofazimine inhalation suspension in NTM lung disease is expected to meet the interim enrollment target by the end of 2025.”